A practical reference on half-life: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-05. Anything still debated is marked as such rather than presented as settled.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Dino Morea (; born 9 December 1975) is an Indian actor and former supermodel who has appeared in Hindi, Tamil, Kannada, Malayalam, and Telugu films. Morea forged a celebrated career in fashion modeling and has been cited in the media as one of India's best supermodels, setting the benchmark for style, presence, and versatility. The 2002 romantic horror Raaz proved to be his breakthrough which was critically and commercially successful and becoming second highest grosser of the year. Subsequently, he featured in several commercially successful films, including, Gunaah (2002), Aksar (2006), Tom Dick Harry (2006) and Happy New Year (2014). He also featured in Baaz (2003), Plan (2004), Holiday (2006), Dus Kahaniyaan (2007), Bhram (2008), and Acid Factory (2009). Following a series of commercial setbacks, his appearances in films became less frequent in the 2010s. In the 2020s, Morea transitioned to streaming platforms, acting in series such as Mentalhood (2020), Hostages (2020), Tandav (2021), Kaun Banegi Shikharwati (2022), The Royals (2025), and Rana Naidu (2025). His performance in The Empire (2021) earned him an Indian Television Academy Award. He marked his comeback in Bollywood with the Housefull 5 (2025). The film was ranked Morea's most commercially successful film, ranking as the year's one of the highest grosser.
=== Pathophysiology of symptoms === Some degree of IRP was detected in up to 50% of people with no symptoms when defecography was carried out on volunteers. However, these findings may have been overstated because of inclusion of clinically insignificant mucosal prolapse and low grade (recto-rectal) IRP, which do not tend to cause any symptoms. Later studies identified factors which determined whether an IRP would cause symptoms or be asymptomatic. IRP which is deeper (recto-anal) and involves the full thickness of the rectal wall tends to cause symptoms. The thickness of rectal folding and the ratio between intussuscipiens diameter and the intussusceptum lumen diameter may also be significant in creating symptoms. Another theory to explain why some cases of IRP are asymptomatic and other cases are symptomatic is that some patients are more susceptible to symptoms in the presence of anatomic abnormalities because of visceral hypersensitivity. This feature is common in functional gastrointestinal disorders, and such patients have a high burden of psychological symptoms. The function of the internal anal sphincter may influence the type of symptoms. In those cases where the internal sphincter has poor function and resting pressure in the anal canal is reduced fecal incontinence may be the main symptom. In those cases where resting pressure is higher, obstructed defecation or solitary rectal ulcer syndrome may develop. In those cases where there is highest resting pressure, there may be chronic idiopathic perineal pain.
European Union officials, European ministers and Commissioner (Tonio) Borg set up an urgent meeting in Brussels on 13 February 2013 on how to contain the horse meat scandal that exposed flaws in European control systems on food safety, and to formulate an action plan. Following the meeting, EU agriculture ministers announced a three-month coordinated control plan of DNA testing of processed meat across the European Union. The plan, adopted 19 February 2013, called for 2,500 random tests on processed food for horse DNA and 4,000 for phenylbutazone (bute), beginning in March 2013, with initial results announced on 15 April 2013. The Hague-based Europol would handle the co-ordination of investigations among national authorities, as well as any raids on premises and arrests on suspicion of criminal conspiracy to defraud.
A transcriptor is a transistor-like device composed of DNA and RNA rather than a semiconducting material such as silicon. Prior to its invention in 2013, the transcriptor was considered an important component to build biological computers. To function, a modern computer needs three different capabilities: It must be able to store information, transmit information between components, and possess a basic system of logic. Prior to March 2013, scientists had successfully demonstrated the ability to store and transmit data using biological components made of proteins and DNA. Simple two-terminal logic gates had been demonstrated, but required multiple layers of inputs and thus were impractical due to scaling difficulties.
Sources: en.wikipedia.org
Seaborg, a scientist at Lawrence Berkeley National Laboratory who had been involved in work to make such superheavy elements, had said in December 1997 that "one of his longest-lasting and most cherished dreams was to see one of these magic elements"; he was told of the synthesis of flerovium by his colleague Albert Ghiorso soon after its publication in 1999. Ghiorso later recalled:
Algolian Babon (アルゴル星人バボン, Arugoru Seijin Babon): Builjeek's partner and an underling of Agent X's from Planet Algol who is equipped with shoulder-mounted missile pods, an arm-mounted blaster, and a magic circle that allows him to absorb the Dekarangers' energy attacks who appears exclusively in the crossover film Mahō Sentai Magiranger vs. Dekaranger. He assists Agent X in obtaining the Flower of Heaven, but both are eventually deleted by the Magirangers and Dekarangers via the Flower of Heaven's power. Babon is voiced by Takashi Nagasako (長嶝 高士, Nagasako Takashi).
In June 2020, TikTok users and K-pop fans "claimed to have registered potentially hundreds of thousands of tickets" for Donald Trump's campaign rally in Tulsa, Oklahoma through communication on TikTok, contributing to "rows of empty seats" at the event. Later, in October 2020, an organization called TikTok for Biden was created to support then-presidential candidate Joe Biden. After the election, the organization was renamed to Gen-Z for Change. On 10 August 2020, Emily Jacobssen wrote and sang "Ode to Remy", a song praising the protagonist from Pixar's 2007 computer-animated film Ratatouille. The song rose to popularity when musician Daniel Mertzlufft composed a backing track to the song. In response, began creating a "crowdsourced" project called Ratatouille the Musical. Since Mertzlufft's video, many new elements including costume design, additional songs, and a playbill have been created. On 1 January 2021, a full one-hour virtual presentation of Ratatouille the Musical premiered on TodayTix. It starred Titus Burgess as Remy, Wayne Brady as Django, Adam Lambert as Emile, Kevin Chamberlin as Gusteau, Andrew Barth Feldman as Linguini, Ashley Park as Colette, Priscilla Lopez as Mabel, Mary Testa as Skinner, and André De Shields as Ego. A viral TikTok trend known as "devious licks" involves students vandalizing or stealing school property and posting videos of the action on the platform. The trend has led to increasing school vandalism and subsequent measures taken by some schools to prevent damage. Some students have been arrested for participating in the trend.
=== Category:EC 2.1 (transfer one-carbon groups, Methylase) === Category:EC 2.1.1 Catechol-O-methyl transferase EC 2.1.1.6 DNA methyltransferase EC 2.1.1.72, EC 2.1.1.113, EC 2.1.1.37 Histone methyltransferase EC 2.1.1.43, EC 2.1.1.125 Category:EC 2.1.3 Aspartate transcarbamoylase EC 2.1.3.2 Ornithine transcarbamoylase EC 2.1.3.3
Intracavernous injection, an injection into the base of the penis. Intradermal, (into the skin itself) is used for skin testing some allergens, and also for mantoux test for tuberculosis. Intralesional (into a skin lesion), is used for local skin lesions, e.g. acne medication. Intramuscular (into a muscle), e.g. many vaccines, antibiotics, and long-term psychoactive agents. Recreationally the colloquial term 'muscling' is used.
Sources: en.wikipedia.org
== Goals of Pharmacometabolomics == Pharmacometabolomics is thought to provide information that complements that gained from other omics, namely genomics, transcriptomics, and proteomics. Looking at the characteristics of an individual down through these different levels of detail, there is an increasingly more accurate prediction of a person's ability to respond to a pharmaceutical compound. The genome, made up of 25 000 genes, can indicate possible errors in drug metabolism; the transcriptome, made up of 85,000 transcripts, can provide information about which genes important in metabolism are being actively transcribed; and the proteome, >10,000,000 members, depicts which proteins are active in the body to carry out these functions. Pharmacometabolomics complements the omics with direct measurement of the products of all of these reactions, but with perhaps a relatively smaller number of members: that was initially projected to be approximately 2200 metabolites, but could be a larger number when gut derived metabolites and xenobiotics are added to the list. Overall, the goal of pharmacometabolomics is to more closely predict or assess the response of an individual to a pharmaceutical compound, permitting continued treatment with the right drug or dosage depending on the variations in their metabolism and ability to respond to treatment. Pharmacometabolomic analyses, through the use of a metabolomics approach, can provide a comprehensive and detailed metabolic profile or "metabolic fingerprint" for an individual patient.
The decrease in BMD during elagolix therapy may not be fully reversible with discontinuation, as only partial recovery was observed 12 months after discontinuation of therapy. The cause of the decrease in BMD with elagolix is estrogen deficiency, and is analogous to that associated with postmenopause. The consequences of the effects of elagolix on BMD are unknown, but may be an increase in the risk of bone loss and fractures. This is why the duration of use of elagolix should be limited. In women with risk factors for bone loss and osteoporosis, such as a history of low-trauma fracture, assessment of BMD may be considered. Elagolix should not be used in premenopausal women with known osteoporosis. Supplementation with calcium and/or vitamin D during treatment with elagolix has not been studied, but may be beneficial for helping to maintain bone health. Elagolix decreases the amount, intensity, and duration of menstrual bleeding. Amenorrhea, the cessation of menstruation, was observed in 4 to 17% of women with 150 mg once per day and in 7 to 57% of women with 200 mg twice per day, compared to less than 1% of women given placebo. The decreased menstrual bleeding caused by elagolix may impede the ability to recognize pregnancy in a timely manner. Based on its mechanism of action, elagolix may increase the risk of miscarriage in early pregnancy, and so should be discontinued if pregnancy occurs. If pregnancy is suspected, pregnancy testing can be performed.
Somalia is a semi-arid country with about 1.6% arable land. The first local environmental organisations were Ecoterra Somalia and the Somali Ecological Society, which promoted ecological awareness and mobilised environmental programs governmentally and through grassroots efforts. From 1971 onward, a massive tree-planting campaign on a nationwide scale was introduced by the communist government to halt the advance of wind-driven sand dunes, which threatened to engulf towns, roads and farm land. By 1988, 265 hectares of a projected 336 hectares had been treated, with 39 range reserve sites and 36 forestry plantation sites established. In 1986, the Wildlife Rescue, Research and Monitoring Centre was established by Ecoterra International, with the goal of raising ecological awareness. This effort led in 1989 to a decision by the Somali government to adhere to the Convention on International Trade in Endangered Species of Wild Fauna and Flora, which banned the trade of elephant ivory. Following the tsunami of December 2004, it was alleged that Somalia's shoreline was used to dump toxic waste. The waves after the tsunami stirred up nuclear and toxic waste that was possibly dumped illegally by foreign firms.
==== Unanimous selection for Most Valuable Player Award (1994) ==== The most productive season in Bagwell's professional career was the strike-shortened 1994 season which set several franchise records. On Opening Day, April 4, against the Montreal Expos, Bagwell hit the game-tying home run while going 3-for-6 as the Astros won in a 12-inning walk-off. For the month of April, he batted .360 with six home runs and added another six home runs in May. In June, he hit 13 home runs, establishing an Astros' franchise record for one month, while batting .394, 11 doubles, .455 OBP, .899 SLG, and 1.354 OPS. On June 24, in a 16–4 rout of the Los Angeles Dodgers at the Astrodome, he hit three home runs, including two in the same inning, becoming the first Astro since Glenn Davis in 1990 to do so. Bagwell was the NL Player of the Week for consecutive weeks on June 19 and June 26 and the NL Player of the Month for June, his second career monthly award. Selected to his first All-Star Game as a reserve, Bagwell had tied Kirby Puckett for the major league RBI lead at 81 going into the All-Star break, and batted .348 with 27 home runs and 74 runs scored. In the All-Star Game, Bagwell entered as a pinch hitter for starting pitcher Greg Maddux, singling off David Cone, and wound up collecting two hits in four at bats. The first player in the majors to reach 100 RBI on July 27, Bagwell homered off José Rijo in a 6–5 win over Cincinnati to give him 101 RBI in his first 101 games. In July, he tied a club record for RBI in any month with 29, which José Cruz and Jimmy Wynn shared.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.